{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:57:12Z","timestamp":1792112232336,"version":"4.4.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Singapore NMRC Research Training Fellowship"},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R35GM141947"],"award-info":[{"award-number":["R35GM141947"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R-257-A14720"],"award-info":[{"award-number":["R-257-A14720"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Maintenance therapy (MT) with oral methotrexate (MTX) and 6-mercaptopurine (6-MP) is essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with nucleotide synthesis and salvage pathways. The primary cytotoxic mechanism involves the incorporation of thioguanine nucleotides (TGNs) into DNA (as DNA-TG), which may be enhanced by the inhibition of de novo purine synthesis by other MTX\/6-MP metabolites. Co-medication during MT is common. Although Pneumocystis jirovecii prophylaxis appears safe, the benefit of glucocorticosteroid\/vincristine pulses in improving survival and of allopurinol to moderate 6-MP pharmacokinetics remains uncertain. Numerous genetic polymorphisms influence the pharmacology, efficacy, and toxicity (mainly myelosuppression and hepatotoxicity) of MTX and thiopurines. Thiopurine S-methyltransferase (encoded by\n                    <jats:italic>TPMT<\/jats:italic>\n                    ) decreases TGNs but increases methylated 6-MP metabolites (MeMPs); similarly, nudix hydrolase 15 (encoded by\n                    <jats:italic>NUDT15<\/jats:italic>\n                    ) also decreases TGNs available for DNA incorporation. Loss-of-function variants in both genes are currently used to guide MT, but do not fully explain the inter-patient variability in thiopurine toxicity. Because of the large inter-individual variations in MTX\/6-MP bioavailability and metabolism, dose adjustments are traditionally guided by the degree of myelosuppression, but this does not accurately reflect treatment intensity. DNA-TG is a common downstream metabolite of MTX\/6-MP combination chemotherapy, and a higher level of DNA-TG has been associated with a lower relapse hazard, leading to the development of the Thiopurine Enhanced ALL Maintenance (TEAM) strategy\u2014the addition of low-dose (2.5\u201312.5\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    \/day) 6-thioguanine to the 6-MP\/MTX backbone\u2014that is currently being tested in a randomized ALLTogether1 trial (EudraCT: 2018-001795-38). Mutations in the thiopurine and MTX metabolism pathways, and in the mismatch repair genes have been identified in early ALL relapses, providing valuable insights to assist the development of strategies to detect imminent relapse, to facilitate relapse salvage therapy, and even to bring about changes in frontline ALL therapy to mitigate this relapse risk.\n                  <\/jats:p>","DOI":"10.1038\/s41375-022-01591-4","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:06:18Z","timestamp":1654167978000},"page":"1749-1758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":130,"title":["Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9871-7637","authenticated-orcid":false,"given":"Linea N.","family":"Toksvang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn H. R.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-9659","authenticated-orcid":false,"given":"Jun J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-4993","authenticated-orcid":false,"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"1591_CR1","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105:2524\u201339.","journal-title":"Haematologica"},{"key":"1591_CR2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM194806032382301","volume":"238","author":"S Farber","year":"1948","unstructured":"Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238:787\u201393.","journal-title":"N Engl J Med"},{"key":"1591_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1126\/science.2649979","volume":"244","author":"G Elion","year":"1989","unstructured":"Elion G. The purine path to chemotherapy. Science. 1989;244:41\u20137.","journal-title":"Science"},{"key":"1591_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood.2020007702","volume":"137","author":"DT Teachey","year":"2021","unstructured":"Teachey DT, Hunger SP, Loh ML. Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. Blood. 2021;137:168\u201377.","journal-title":"Blood"},{"key":"1591_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(96)91615-3","volume":"347","author":"Childhood ALL Collaborative Group","year":"1996","unstructured":"Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children. Lancet. 1996;347:1783\u20138.","journal-title":"Lancet"},{"key":"1591_CR6","doi-asserted-by":"crossref","unstructured":"Gupta S, Teachey DT, Chen Z, Rabin KR, Dunsmore KP, Larsen EC, et al. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children\u2019s Oncology Group report. Cancer. 2022;128:1863\u201370.","DOI":"10.1002\/cncr.34150"},{"key":"1591_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/leu.2016.274","volume":"31","author":"M Kato","year":"2017","unstructured":"Kato M, Ishimaru S, Seki M, Yoshida K, Shiraishi Y, Chiba K, et al. Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. Leukemia. 2017;31:580\u20134.","journal-title":"Leukemia"},{"key":"1591_CR8","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985;76:907\u201312.","journal-title":"J Clin Invest"},{"key":"1591_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MPH.0000000000000206","volume":"36","author":"K Schmiegelow","year":"2014","unstructured":"Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine\/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol. 2014;36:503\u201317.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1591_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00280-018-3704-7","volume":"83","author":"J Nersting","year":"2019","unstructured":"Nersting J, Nielsen SN, Grell K, Paerregaard M, Abrahamsson J, Lund B, et al. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy. Cancer Chemother Pharm. 2019;83:53\u201360.","journal-title":"Cancer Chemother Pharm"},{"key":"1591_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","volume":"146","author":"K Schmiegelow","year":"2009","unstructured":"Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146:489\u2013503.","journal-title":"Br J Haematol"},{"key":"1591_CR12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJM198304283081705","volume":"308","author":"S Zimm","year":"1983","unstructured":"Zimm S, Collins JM, Riccardi R, O\u2019Neill D, Narang PK, Chabner B, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N. Engl J Med. 1983;308:1005\u20139.","journal-title":"N. Engl J Med"},{"key":"1591_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc2292","volume":"8","author":"P Karran","year":"2008","unstructured":"Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer. 2008;8:24\u201336.","journal-title":"Nat Rev Cancer"},{"key":"1591_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1470-2045(17)30154-7","volume":"18","author":"SN Nielsen","year":"2017","unstructured":"Nielsen SN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, et al. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial. Lancet Oncol. 2017;18:515\u201324.","journal-title":"Lancet Oncol"},{"key":"1591_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41375-021-01182-9","volume":"36","author":"LN Toksvang","year":"2022","unstructured":"Toksvang LN, Grell K, Nersting J, Degn M, Nielsen SN, Abrahamsson J, et al. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis. Leukemia. 2022;36:33\u201341.","journal-title":"Leukemia"},{"key":"1591_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0145-2126(94)90159-7","volume":"18","author":"PC Adamson","year":"1994","unstructured":"Adamson PC, Poplack DG, Balis FM. The cytotoxicity of thioguanine vs mercaptopurine in acute lymphoblastic leukemia. Leuk Res. 1994;18:805\u201310.","journal-title":"Leuk Res"},{"key":"1591_CR17","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(06)69558-5","volume":"368","author":"A Vora","year":"2006","unstructured":"Vora A, Mitchell CD, Lennard L, Eden TOB, Kinsey SE, Lilleyman J, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet. 2006;368:1339\u201348.","journal-title":"Lancet"},{"key":"1591_CR18","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood-2002-08-2372","volume":"102","author":"DO Harms","year":"2003","unstructured":"Harms DO, Gobel U, Spaar HJ, Graubner UB, Jorch N, Gutjahr P, et al. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92. Blood. 2003;102:2736\u201340.","journal-title":"Blood"},{"key":"1591_CR19","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/blood-2009-07-230656","volume":"115","author":"LC Stork","year":"2010","unstructured":"Stork LC, Matloub Y, Broxson E, La M, Yanofsky R, Sather H, et al. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children\u2019s Oncology Group CCG-1952 clinical trial. Blood. 2010;115:2740\u20138.","journal-title":"Blood"},{"key":"1591_CR20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/leu.2011.37","volume":"25","author":"G Escherich","year":"2011","unstructured":"Escherich G, Richards S, Stork LC, Vora AJ, Childhood Acute Lymphoblastic Leukaemia Collaborative G. Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia. 2011;25:953\u20139.","journal-title":"Leukemia"},{"key":"1591_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s002800050816","volume":"42","author":"N Erb","year":"1998","unstructured":"Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharm. 1998;42:266\u201372.","journal-title":"Cancer Chemother Pharm"},{"key":"1591_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41375-021-01420-0","volume":"36","author":"LN Toksvang","year":"2022","unstructured":"Toksvang LN, Grell K, Nielsen SN, Nersting J, Murdy D, Moorman AV, et al. DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia. Leukemia. 2022;36:555\u20137.","journal-title":"Leukemia"},{"key":"1591_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s002800050405","volume":"37","author":"F Innocenti","year":"1996","unstructured":"Innocenti F, Danesi R, Di Paolo A, Loru B, Favre C, Nardi M, et al. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate. Cancer Chemother Pharm. 1996;37:409\u201314.","journal-title":"Cancer Chemother Pharm"},{"key":"1591_CR24","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/0006-2952(88)90358-9","volume":"37","author":"JP B\u00f6kkerink","year":"1988","unstructured":"B\u00f6kkerink JP, Bakker MA, Hulscher TW, De Abreu RA, Schretlen ED. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharm. 1988;37:2321\u20137.","journal-title":"Biochem Pharm"},{"key":"1591_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/sj.leu.2402373","volume":"16","author":"T Dervieux","year":"2002","unstructured":"Dervieux T, Hancock M, Evans W, Pui C-H, Relling MV. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia. 2002;16:209\u201312.","journal-title":"Leukemia"},{"key":"1591_CR26","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00280-016-3151-2","volume":"78","author":"SN Nielsen","year":"2016","unstructured":"Nielsen SN, Grell K, Nersting J, Frandsen TL, Hjalgrim LL, Schmiegelow K. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia. Cancer Chemother Pharm. 2016;78:983\u201394.","journal-title":"Cancer Chemother Pharm"},{"key":"1591_CR27","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3324\/haematol.2020.278166","volume":"106","author":"RH Larsen","year":"2021","unstructured":"Larsen RH, Utke Rank C, Grell K, N\u00f8rgaard M\u00f8ller L, Malthe Overgaard U, Kampmann P, et al. Increments in DNA-thioguanine level during thiopurine enhanced maintenance therapy of acute lymphoblastic leukemia. Haematologica. 2021;106:2824\u201333.","journal-title":"Haematologica"},{"key":"1591_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MPH.0000000000000733","volume":"39","author":"MS Ebbesen","year":"2017","unstructured":"Ebbesen MS, Nygaard U, Rosthoj S, Sorensen D, Nersting J, Vettenranta K, et al. Hepatotoxicity during maintenance therapy and prognosis in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2017;39:161\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1591_CR29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.clpt.2003.12.001","volume":"75","author":"U Nygaard","year":"2004","unstructured":"Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharm Ther. 2004;75:274\u201381.","journal-title":"Clin Pharm Ther"},{"key":"1591_CR30","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/pbc.24928","volume":"61","author":"S Melachuri","year":"2014","unstructured":"Melachuri S, Gandrud L, Bostrom B. The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014;61:1003\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"1591_CR31","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bcp.2013.06.002","volume":"86","author":"PA Blaker","year":"2013","unstructured":"Blaker PA, Arenas-Hernandez M, Smith MA, Shobowale-Bakre EA, Fairbanks L, Irving PM, et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharm. 2013;86:539\u201347.","journal-title":"Biochem Pharm"},{"key":"1591_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MPH.0000000000002117","volume":"43","author":"R Kamojjala","year":"2021","unstructured":"Kamojjala R, Bostrom B. Allopurinol to prevent mercaptopurine adverse effects in children and young adults with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2021;43:95\u2013100.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1591_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00280-021-04281-7","volume":"88","author":"SN Nielsen","year":"2021","unstructured":"Nielsen SN, Toksvang LN, Grell K, Nersting J, Abrahamsson J, Lund B, et al. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study. Cancer Chemother Pharm. 2021;88:271\u20139.","journal-title":"Cancer Chemother Pharm"},{"key":"1591_CR34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2005-08-3379","volume":"107","author":"MV Relling","year":"2006","unstructured":"Relling MV, Pui CH, Cheng C, Evans WE. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood. 2006;107:843\u20134.","journal-title":"Blood"},{"key":"1591_CR35","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.eclinm.2022.101332","volume":"45","author":"M Kiszka-Kanowitz","year":"2022","unstructured":"Kiszka-Kanowitz M, Theede K, Thomsen SB, Bjerrum JT, Brynskov J, Gottschalck IB, et al. Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): an investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial. EClinicalMedicine. 2022;45:101332.","journal-title":"EClinicalMedicine"},{"key":"1591_CR36","first-page":"1396","volume":"90","author":"S Cesaro","year":"2005","unstructured":"Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica. 2005;90:1396\u2013404.","journal-title":"Haematologica"},{"key":"1591_CR37","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1038\/s41375-021-01203-7","volume":"35","author":"M Stanulla","year":"2021","unstructured":"Stanulla M, Schaeffeler E, M\u00f6ricke A, Buchmann S, Zimmermann M, Igel S, et al. Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia. 2021;35:2650\u20137.","journal-title":"Leukemia"},{"key":"1591_CR38","doi-asserted-by":"publisher","first-page":"444","DOI":"10.12688\/f1000research.10768.1","volume":"6","author":"K Schmiegelow","year":"2017","unstructured":"Schmiegelow K, M\u00fcller K, Mogensen SS, Mogensen PR, Wolthers BO, Stoltze UK, et al. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Research. 2017;6:444.","journal-title":"F1000Research"},{"key":"1591_CR39","doi-asserted-by":"publisher","first-page":"e0212157","DOI":"10.1371\/journal.pone.0212157","volume":"14","author":"LN Toksvang","year":"2019","unstructured":"Toksvang LN, Schmidt MS, Arup S, Larsen RH, Frandsen TL, Schmiegelow K, et al. Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review. PLoS ONE. 2019;14:e0212157.","journal-title":"PLoS ONE"},{"key":"1591_CR40","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/bloodadvances.2018026211","volume":"3","author":"J Wynne","year":"2019","unstructured":"Wynne J, Wright D, Stock W. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019;3:96\u2013104.","journal-title":"Blood Adv"},{"key":"1591_CR41","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/pbc.26139","volume":"63","author":"K Schmiegelow","year":"2016","unstructured":"Schmiegelow K, Nersting J, Nielsen SN, Heyman M, Wesenberg F, Kristinsson J, et al. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts? Pediatr Blood Cancer. 2016;63:2104\u201311.","journal-title":"Pediatr Blood Cancer"},{"key":"1591_CR42","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood.V93.9.2817","volume":"93","author":"MV Relling","year":"1999","unstructured":"Relling MV, Hancock ML, Boyett JM, Pui CH, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93:2817\u201323.","journal-title":"Blood"},{"key":"1591_CR43","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1200\/JCO.2003.04.039","volume":"21","author":"K Schmiegelow","year":"2003","unstructured":"Schmiegelow K, Bjork O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, et al. Intensification of mercaptopurine\/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21:1332\u20139.","journal-title":"J Clin Oncol"},{"key":"1591_CR44","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1200\/JCO.2012.47.0500","volume":"31","author":"K Schmiegelow","year":"2013","unstructured":"Schmiegelow K, Levinsen MF, Attarbaschi A, Baruchel A, Devidas M, Escherich G, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2013;31:2469\u201376.","journal-title":"J Clin Oncol"},{"key":"1591_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3109\/08880019109028803","volume":"8","author":"K Schmiegelow","year":"1991","unstructured":"Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1991;8:301\u201312.","journal-title":"Pediatr Hematol Oncol"},{"key":"1591_CR46","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/pbc.24867","volume":"61","author":"KK Clemmensen","year":"2014","unstructured":"Clemmensen KK, Christensen RH, Shabaneh DN, Harila-Saari A, Heyman M, Jonsson OG, et al. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol. Pediatr Blood Cancer. 2014;61:653\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"1591_CR47","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1200\/JCO.2016.71.7579","volume":"35","author":"W Landier","year":"2017","unstructured":"Landier W, Hageman L, Chen Y, Kornegay N, Evans WE, Bostrom BC, et al. Mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, and relapse risk in children with acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group study AALL03N1. J Clin Oncol. 2017;35:1730\u20136.","journal-title":"J Clin Oncol"},{"key":"1591_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1600-0609.2011.01695.x","volume":"88","author":"M Levinsen","year":"2012","unstructured":"Levinsen M, Shabaneh D, Bohnstedt C, Harila-Saari A, Jonsson OG, Kanerva J, et al. Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate\/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia. Eur J Haematol. 2012;88:78\u201386.","journal-title":"Eur J Haematol"},{"key":"1591_CR49","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1365-2141.2010.08148.x","volume":"149","author":"T Eden","year":"2010","unstructured":"Eden T, Pieters R, Richards S. Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia - an individual patient data meta-analysis involving 5659 children. Br J Haematol. 2010;149:722\u201333.","journal-title":"Br J Haematol"},{"key":"1591_CR50","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1038\/leu.2015.134","volume":"29","author":"E Clappier","year":"2015","unstructured":"Clappier E, Grardel N, Bakkus M, Rapion J, De Moerloose B, Kastner P, et al. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children\u2019s Leukemia Group study 58951. Leukemia. 2015;29:2154\u201361.","journal-title":"Leukemia"},{"key":"1591_CR51","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.20.00494","volume":"39","author":"AL Angiolillo","year":"2021","unstructured":"Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Excellent outcomes with reduced frequency of Vincristine and Dexamethasone pulses in standard-risk B-Lymphoblastic leukemia: results from Children\u2019s Oncology Group AALL0932. J Clin Oncol. 2021;39:1437\u201347.","journal-title":"J Clin Oncol"},{"key":"1591_CR52","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/S1470-2045(21)00328-4","volume":"22","author":"W Yang","year":"2021","unstructured":"Yang W, Cai J, Shen S, Gao J, Yu J, Hu S, et al. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22:1322\u201332.","journal-title":"Lancet Oncol"},{"key":"1591_CR53","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood.2019001557","volume":"135","author":"DT Teachey","year":"2020","unstructured":"Teachey DT, O\u2019Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood. 2020;135:159\u201366.","journal-title":"Blood"},{"key":"1591_CR54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/MPH.0b013e3181a6e171","volume":"31","author":"K Schmiegelow","year":"2009","unstructured":"Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosth\u00f8j S, Vettenranta K, et al. Oral methotrexate\/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. J Pediatr Hematol Oncol. 2009;31:385\u201392.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1591_CR55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.beha.2017.07.007","volume":"30","author":"SHR Lee","year":"2017","unstructured":"Lee SHR, Yang JJ. Pharmacogenomics in acute lymphoblastic leukemia. Best Pr Res Clin Haematol. 2017;30:229\u201336.","journal-title":"Best Pr Res Clin Haematol"},{"key":"1591_CR56","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/cpt.1304","volume":"105","author":"MV Relling","year":"2019","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 Update. Clin Pharm Ther. 2019;105:1095\u2013105.","journal-title":"Clin Pharm Ther"},{"key":"1591_CR57","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/jnci\/91.23.2001","volume":"91","author":"MV Relling","year":"1999","unstructured":"Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1591_CR58","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00280-018-3525-8","volume":"81","author":"T Gerbek","year":"2018","unstructured":"Gerbek T, Ebbesen M, Nersting J, Frandsen TL, Appell ML, Schmiegelow K. Role of TPMT and ITPA variants in mercaptopurine disposition. Cancer Chemother Pharm. 2018;81:579\u201386.","journal-title":"Cancer Chemother Pharm"},{"key":"1591_CR59","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/leu.2008.316","volume":"23","author":"K Schmiegelow","year":"2009","unstructured":"Schmiegelow K, Forestier E, Kristinsson J, S\u00f6derh\u00e4ll S, Vettenranta K, Weinshilboum R, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia. 2009;23:557\u201364.","journal-title":"Leukemia"},{"key":"1591_CR60","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1200\/JCO.2014.59.4671","volume":"33","author":"JJ Yang","year":"2015","unstructured":"Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33:1235\u201342.","journal-title":"J Clin Oncol"},{"key":"1591_CR61","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3508","volume":"48","author":"T Moriyama","year":"2016","unstructured":"Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48:367\u201373.","journal-title":"Nat Genet"},{"key":"1591_CR62","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1073\/pnas.1915680117","volume":"117","author":"CC Suiter","year":"2020","unstructured":"Suiter CC, Moriyama T, Matreyek KA, Yang W, Scaletti ER, Nishii R, et al. Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity. Proc Natl Acad Sci USA. 2020;117:5394\u2013401.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1591_CR63","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2217\/14622416.8.9.1221","volume":"8","author":"J Bierau","year":"2007","unstructured":"Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics. 2007;8:1221\u20138.","journal-title":"Pharmacogenomics"},{"key":"1591_CR64","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/clpt.2008.154","volume":"85","author":"G Stocco","year":"2009","unstructured":"Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharm Ther. 2009;85:164\u201372.","journal-title":"Clin Pharm Ther"},{"key":"1591_CR65","doi-asserted-by":"publisher","first-page":"e45558","DOI":"10.1371\/journal.pone.0045558","volume":"7","author":"H Kim","year":"2012","unstructured":"Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y, et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS ONE. 2012;7:e45558.","journal-title":"PLoS ONE"},{"key":"1591_CR66","doi-asserted-by":"publisher","first-page":"e109551","DOI":"10.1371\/journal.pone.0109551","volume":"9","author":"A Smid","year":"2014","unstructured":"Smid A, Karas-Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I. Association of ITPA genotype with event-free survival and relapse rates in children with acute lymphoblastic leukemia undergoing maintenance therapy. PLoS ONE. 2014;9:e109551.","journal-title":"PLoS ONE"},{"key":"1591_CR67","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1182\/blood.2020005064","volume":"136","author":"M Tulstrup","year":"2020","unstructured":"Tulstrup M, Moriyama T, Jiang C, Grosjean M, Nersting J, Abrahamsson J, et al. Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia. Blood. 2020;136:1161\u20138.","journal-title":"Blood"},{"key":"1591_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/gr.129668.111","volume":"22","author":"LB Ramsey","year":"2012","unstructured":"Ramsey LB, Bruun GH, Yang W, Trevi\u00f1o LR, Vattathil S, Scheet P, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 2012;22:1\u20138.","journal-title":"Genome Res"},{"key":"1591_CR69","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1097\/MPH.0000000000001153","volume":"40","author":"\u0130 Eldem","year":"2018","unstructured":"Eldem \u0130, Yavuz D, Cumao\u011fullari \u00d6, \u0130leri T, \u00dcnal \u0130nce E, Ertem M, et al. SLCO1B1 polymorphisms are associated with drug intolerance in childhood leukemia maintenance therapy. J Pediatr Hematol Oncol. 2018;40:e289\u2013e94.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1591_CR70","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/ped.12682","volume":"57","author":"R Suzuki","year":"2015","unstructured":"Suzuki R, Fukushima H, Noguchi E, Tsuchida M, Kiyokawa N, Koike K, et al. Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia. Pediatr Int. 2015;57:572\u20137.","journal-title":"Pediatr Int"},{"key":"1591_CR71","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00228-011-1133-1","volume":"68","author":"P Dorababu","year":"2012","unstructured":"Dorababu P, Nagesh N, Linga VG, Gundeti S, Kutala VK, Reddanna P, et al. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur J Clin Pharm. 2012;68:379\u201387.","journal-title":"Eur J Clin Pharm"},{"key":"1591_CR72","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/nm.4410","volume":"23","author":"AA Ferrando","year":"2017","unstructured":"Ferrando AA, L\u00f3pez-Ot\u00edn C. Clonal evolution in leukemia. Nat Med. 2017;23:1135\u201345.","journal-title":"Nat Med"},{"key":"1591_CR73","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nature25186","volume":"553","author":"G Tzoneva","year":"2018","unstructured":"Tzoneva G, Dieck CL, Oshima K, Ambesi-Impiombato A, Sanchez-Martin M, Madubata CJ, et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature. 2018;553:511\u20134.","journal-title":"Nature"},{"key":"1591_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7604","volume":"6","author":"X Ma","year":"2015","unstructured":"Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun. 2015;6:6604.","journal-title":"Nat Commun"},{"key":"1591_CR75","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ng.2558","volume":"45","author":"JA Meyer","year":"2013","unstructured":"Meyer JA, Wang J, Hogan LE, Yang JJ, Dandekar S, Patel JP, et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet. 2013;45:290\u20134.","journal-title":"Nat Genet"},{"key":"1591_CR76","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1182\/blood.2019002499","volume":"135","author":"MJ Barz","year":"2020","unstructured":"Barz MJ, Hof J, Groeneveld-Krentz S, Loh JW, Szymansky A, Astrahantseff K, et al. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia. Blood. 2020;135:921\u201333.","journal-title":"Blood"},{"key":"1591_CR77","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1182\/blood-2019-01-852392","volume":"133","author":"CL Dieck","year":"2019","unstructured":"Dieck CL, Ferrando A. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL. Blood. 2019;133:2263\u20138.","journal-title":"Blood"},{"key":"1591_CR78","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1158\/1535-7163.MCT-18-1112","volume":"18","author":"T Moriyama","year":"2019","unstructured":"Moriyama T, Liu S, Li J, Meyer J, Zhao X, Yang W, et al. Mechanisms of NT5C2-mediated thiopurine resistance in acute lymphoblastic leukemia. Mol Cancer Ther. 2019;18:1887\u201395.","journal-title":"Mol Cancer Ther"},{"key":"1591_CR79","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1038\/s41375-018-0245-3","volume":"32","author":"M Tulstrup","year":"2018","unstructured":"Tulstrup M, Grosjean M, Nielsen SN, Grell K, Wolthers BO, Wegener PS, et al. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. Leukemia. 2018;32:2527\u201335.","journal-title":"Leukemia"},{"key":"1591_CR80","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nm.3840","volume":"21","author":"B Li","year":"2015","unstructured":"Li B, Li H, Bai Y, Kirschner-Schwabe R, Yang JJ, Chen Y, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat Med. 2015;21:563\u201371.","journal-title":"Nat Med"},{"key":"1591_CR81","doi-asserted-by":"publisher","first-page":"6202","DOI":"10.1111\/jcmm.13907","volume":"22","author":"D Wang","year":"2018","unstructured":"Wang D, Chen Y, Fang H, Zheng L, Li Y, Yang F, et al. Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5-Fluorouracil. J Cell Mol Med. 2018;22:6202\u201312.","journal-title":"J Cell Mol Med"},{"key":"1591_CR82","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3324\/haematol.2017.176362","volume":"103","author":"NA Evensen","year":"2018","unstructured":"Evensen NA, Madhusoodhan PP, Meyer J, Saliba J, Chowdhury A, Araten DJ, et al. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia. Haematologica. 2018;103:830\u20139.","journal-title":"Haematologica"},{"key":"1591_CR83","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood.2019002220","volume":"135","author":"B Li","year":"2020","unstructured":"Li B, Brady SW, Ma X, Shen S, Zhang Y, Li Y, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020;135:41\u201355.","journal-title":"Blood"},{"key":"1591_CR84","doi-asserted-by":"publisher","first-page":"e28306","DOI":"10.1002\/pbc.28306","volume":"67","author":"J Saliba","year":"2020","unstructured":"Saliba J, Evensen NA, Meyer JA, Newman D, Nersting J, Narang S, et al. Feasibility of monitoring peripheral blood to detect emerging clones in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67:e28306.","journal-title":"Pediatr Blood Cancer"},{"key":"1591_CR85","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1182\/blood-2008-11-187880","volume":"113","author":"K Schmiegelow","year":"2009","unstructured":"Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H, et al. Methotrexate\/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood. 2009;113:6077\u201384.","journal-title":"Blood"},{"key":"1591_CR86","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1182\/blood-2008-12-193250","volume":"114","author":"M Stanulla","year":"2009","unstructured":"Stanulla M, Schaeffeler E, M\u00f6ricke A, Coulthard SA, Cario G, Schrauder A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-M\u00fcnster protocols. Blood. 2009;114:1314\u20138.","journal-title":"Blood"},{"key":"1591_CR87","doi-asserted-by":"publisher","first-page":"e26518","DOI":"10.1002\/pbc.26518","volume":"64","author":"SN Nielsen","year":"2017","unstructured":"Nielsen SN, Eriksson F, Rosthoej S, Andersen MK, Forestier E, Hasle H, et al. Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers. Pediatr Blood Cancer. 2017;64:e26518.","journal-title":"Pediatr Blood Cancer"},{"key":"1591_CR88","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/MPH.0b013e3182a8f23f","volume":"36","author":"M Bansal","year":"2014","unstructured":"Bansal M, Sharma KK, Bakhshi S, Vatsa M. Perception of indian parents on health-related quality of life of children during maintenance therapy of acute lymphoblastic leukemia: a comparison with siblings and healthy children. J Pediatr Hematol Oncol. 2014;36:30\u20136.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1591_CR89","doi-asserted-by":"publisher","first-page":"e28697","DOI":"10.1002\/pbc.28697","volume":"67","author":"N Rensen","year":"2020","unstructured":"Rensen N, Steur LMH, Grootenhuis MA, van Eijkelenburg NKA, van der Sluis IM, Dors N, et al. Parental functioning during maintenance treatment for childhood acute lymphoblastic leukemia: effects of treatment intensity and dexamethasone pulses. Pediatr Blood Cancer. 2020;67:e28697.","journal-title":"Pediatr Blood Cancer"},{"key":"1591_CR90","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1043454213520346","volume":"31","author":"M Neu","year":"2014","unstructured":"Neu M, Matthews E, King NA, Cook PF, Laudenslager ML. Anxiety, depression, stress, and cortisol levels in mothers of children undergoing maintenance therapy for childhood acute lymphoblastic leukemia. J Pediatr Oncol Nurs. 2014;31:104\u201313.","journal-title":"J Pediatr Oncol Nurs"},{"key":"1591_CR91","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1007\/s00520-020-05444-7","volume":"28","author":"LMH Steur","year":"2020","unstructured":"Steur LMH, Kaspers GJL, van Someren EJW, van Eijkelenburg NKA, van der Sluis IM, Dors N, et al. The impact of maintenance therapy on sleep-wake rhythms and cancer-related fatigue in pediatric acute lymphoblastic leukemia. Support Care Cancer. 2020;28:5983\u201393.","journal-title":"Support Care Cancer"},{"key":"1591_CR92","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/01.mph.0000243666.79303.45","volume":"28","author":"MT Pritchard","year":"2006","unstructured":"Pritchard MT, Butow PN, Stevens MM, Duley JA. Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review. J Pediatr Hematol Oncol. 2006;28:816\u201323.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1591_CR93","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1182\/blood-2014-01-552166","volume":"124","author":"S Bhatia","year":"2014","unstructured":"Bhatia S, Landier W, Hageman L, Kim H, Chen Y, Crews KR, et al. 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children\u2019s Oncology Group study. Blood. 2014;124:2345\u201353.","journal-title":"Blood"},{"key":"1591_CR94","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2011.38.9924","volume":"30","author":"S Bhatia","year":"2012","unstructured":"Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, et al. Nonadherence to oral mercaptopurine and risk of relapse in hispanic and non-hispanic white children with acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2012;30:2094\u2013101.","journal-title":"J Clin Oncol"},{"key":"1591_CR95","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2016-07-726893","volume":"129","author":"W Landier","year":"2017","unstructured":"Landier W, Chen Y, Hageman L, Kim H, Bostrom BC, Casillas JN, et al. Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children\u2019s Oncology Group study. Blood. 2017;129:1919\u201326.","journal-title":"Blood"},{"key":"1591_CR96","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaoncol.2015.0245","volume":"1","author":"S Bhatia","year":"2015","unstructured":"Bhatia S, Landier W, Hageman L, Chen Y, Kim H, Sun CL, et al. Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: a children\u2019s oncology group study. JAMA Oncol. 2015;1:287\u201395.","journal-title":"JAMA Oncol"},{"key":"1591_CR97","doi-asserted-by":"publisher","first-page":"e2014205","DOI":"10.1001\/jamanetworkopen.2020.14205","volume":"3","author":"S Bhatia","year":"2020","unstructured":"Bhatia S, Hageman L, Chen Y, Wong FL, McQuaid EL, Duncan C, et al. Effect of a daily text messaging and directly supervised therapy intervention on oral mercaptopurine adherence in children with acute lymphoblastic leukemia: a randomized clinical trial. JAMA Netw Open. 2020;3:e2014205.","journal-title":"JAMA Netw Open"},{"key":"1591_CR98","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/MPH.0000000000001530","volume":"41","author":"P Kandikonda","year":"2019","unstructured":"Kandikonda P, Bostrom B. Methotrexate polyglutamate values in children and adolescents with acute lymphoblastic leukemia during maintenance therapy. J Pediatr Hematol Oncol. 2019;41:429\u201332.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1591_CR99","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jpepsy\/jsw039","volume":"42","author":"JM Rohan","year":"2017","unstructured":"Rohan JM, Fukuda T, Alderfer MA, Wetherington Donewar C, Ewing L, Katz ER, et al. Measuring medication adherence in pediatric cancer: an approach to validation. J Pediatr Psychol. 2017;42:232\u201344.","journal-title":"J Pediatr Psychol"},{"key":"1591_CR100","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/ejh.13711","volume":"108","author":"ER Kristj\u00e1nsd\u00f3ttir","year":"2022","unstructured":"Kristj\u00e1nsd\u00f3ttir ER, Toksvang LN, Schmiegelow K, Rank CU. Prevalence of non-adherence and non-compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival. Eur J Haematol. 2022;108:109\u201317.","journal-title":"Eur J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01591-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01591-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01591-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T16:03:07Z","timestamp":1668355387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01591-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":100,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1591"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01591-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"27 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JJY receives research funding from the Takeda Pharmaceutical Company. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}